Response of the adrenal cortex to tetracosactrin (ACTH1-24) in the premature and full-term foal.

Rossdale PD, Silver M, Ellis L, Frauenfelder H

Journal of reproduction and fertility. Supplement1 Jan 1982Cited by 17 (Europe PMC)

PMID6300391PepBankPUB-06300391

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

1 result from studies that gave the peptide. No result from this study comes from people.

01AnimalAnimal study (in vivo)Activity measurement
In term and premature foals, depot tetracosactrin appeared to increase basal cortisol levels 3-fold.
In plain wordsIn term and premature foals, depot tetracosactrin appeared to increase resting cortisol levels threefold.
Peptide
Cosyntropin
Outcome
IncreaseBasal cortisol after depot tetracosactrin
Study
horsen: not reported in source
Newborn term and premature foals
Outcome group
Adrenal Function · Endocrine and hormones
Studied dose
3 doses: 0.4, 0.2, 0.2 mg · intramuscular · 24 hAs given in this study (horse).
Measurements
Basal cortisol increase
3 fold
both groups
Source sentences
Summary
The depot tetracosactrin also appeared to cause a 3-fold increase in basal plasma cortisol levels in both groups.
2 context sentences(design, population, supporting numbers)
Summary · context
After a 24-h period of treatment with depot tetracosactrin (3 doses; 0.4, 0.2, 0.2 mg i.m.), a 2nd test with short-acting tetracosactrin led to a rise in plasma cortisol in term and pre-term foals during the 2-h test period.
Summary · context
The changes in plasma cortisol concentration in the immediate postnatal period were examined in 3 groups of newborn foals and the response of the adrenal cortex to exogenous ACTH1-24 (tetracosactrin) was tested in 2 of these groups.
Report a problemFND-0630039106

Studies that did not test the peptide alone5

In this study, Cosyntropin was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Cosyntropin.

02AnimalNot a test of Cosyntropin aloneAnimal study (in vivo)Activity measurement
In term foals, a single 0.125 mg intramuscular tetracosactrin injection produced a rapid cortisol rise during the 2-h test.
In plain wordsIn term foals, cortisol rose rapidly after tetracosactrin injection.
Peptide
Cosyntropin
Outcome
IncreaseCortisol response in term foals
Study
horsen: not reported in source
Newborn term and premature foals
Outcome group
Adrenal Function · Endocrine and hormones
Measurements
Dose
0.125 mg
single intramuscular injection
Source sentences
Summary
When short-acting tetracosactrin was given as a single i.m. injection (0.125 mg), a rapid rise in plasma cortisol occurred in all term foals whereas no response was detected in the premature group during the same 2-h test period.
1 context sentence(design, population, supporting numbers)
Summary · context
The changes in plasma cortisol concentration in the immediate postnatal period were examined in 3 groups of newborn foals and the response of the adrenal cortex to exogenous ACTH1-24 (tetracosactrin) was tested in 2 of these groups.
In this study, Cosyntropin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cosyntropin.
Report a problemFND-0630039101
03AnimalNot a test of Cosyntropin aloneAnimal study (in vivo)Activity measurement
In premature foals, a single 0.125 mg intramuscular tetracosactrin injection produced no detectable cortisol response during the 2-h test.
In plain wordsIn premature foals, tetracosactrin injection produced no detectable cortisol response during the test.
Peptide
Cosyntropin
Outcome
No significant changeCortisol response in premature foals
Study
horsen: not reported in source
Newborn term and premature foals
Outcome group
Adrenal Function · Endocrine and hormones
Source sentences
Summary
When short-acting tetracosactrin was given as a single i.m. injection (0.125 mg), a rapid rise in plasma cortisol occurred in all term foals whereas no response was detected in the premature group during the same 2-h test period.
1 context sentence(design, population, supporting numbers)
Summary · context
The changes in plasma cortisol concentration in the immediate postnatal period were examined in 3 groups of newborn foals and the response of the adrenal cortex to exogenous ACTH1-24 (tetracosactrin) was tested in 2 of these groups.
In this study, Cosyntropin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cosyntropin.
Report a problemFND-0630039102
04AnimalNot a test of Cosyntropin aloneAnimal study (in vivo)Activity measurement
In term foals, the tetracosactrin adrenal response accompanied a significant decrease in the neutrophil/lymphocyte ratio at 2 h.
In plain wordsIn term foals, the blood cell ratio fell significantly after tetracosactrin injection.
Peptide
Cosyntropin
Outcome
DecreaseNeutrophil/lymphocyte ratio in term foals
Study
horsen: not reported in source
Newborn term and premature foals
Outcome group
Immune response · Immune and inflammation
Source sentences
Summary
The adrenal cortical response was also accompanied by a significant fall in the neutrophil/lymphocyte ratio at 2 h after the injection; no such change was seen in the premature animals.
2 context sentences(design, population, supporting numbers)
Summary · context
When short-acting tetracosactrin was given as a single i.m. injection (0.125 mg), a rapid rise in plasma cortisol occurred in all term foals whereas no response was detected in the premature group during the same 2-h test period.
Summary · context
The changes in plasma cortisol concentration in the immediate postnatal period were examined in 3 groups of newborn foals and the response of the adrenal cortex to exogenous ACTH1-24 (tetracosactrin) was tested in 2 of these groups.
In this study, Cosyntropin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cosyntropin.
Report a problemFND-0630039103
05AnimalNot a test of Cosyntropin aloneAnimal study (in vivo)Activity measurement
In premature foals, the neutrophil/lymphocyte ratio did not change after tetracosactrin injection.
In plain wordsIn premature foals, the blood cell ratio did not change after tetracosactrin injection.
Peptide
Cosyntropin
Outcome
No significant changeNeutrophil/lymphocyte ratio in premature foals
Study
horsen: not reported in source
Newborn term and premature foals
Outcome group
Immune response · Immune and inflammation
Source sentences
Summary
The adrenal cortical response was also accompanied by a significant fall in the neutrophil/lymphocyte ratio at 2 h after the injection; no such change was seen in the premature animals.
1 context sentence(design, population, supporting numbers)
Summary · context
The changes in plasma cortisol concentration in the immediate postnatal period were examined in 3 groups of newborn foals and the response of the adrenal cortex to exogenous ACTH1-24 (tetracosactrin) was tested in 2 of these groups.
In this study, Cosyntropin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cosyntropin.
Report a problemFND-0630039104
06AnimalNot a test of Cosyntropin aloneAnimal study (in vivo)Activity measurement
In term and pre-term foals, repeat short-acting tetracosactrin testing increased cortisol after 24-h depot tetracosactrin treatment with 0.4, 0.2, and 0.2 mg.
In plain wordsIn term and pre-term foals, cortisol rose during repeat tetracosactrin testing after depot treatment.
Peptide
Cosyntropin
Outcome
IncreaseRepeat cortisol response after depot treatment
Study
horsen: not reported in source
Newborn term and premature foals
Outcome group
Adrenal Function · Endocrine and hormones
Measurements
Treatment duration
24 h
depot tetracosactrin
Dose
0.4 mg
first depot dose
Dose
0.2 mg
second depot dose
Dose
0.2 mg
third depot dose
Source sentences
Summary
After a 24-h period of treatment with depot tetracosactrin (3 doses; 0.4, 0.2, 0.2 mg i.m.), a 2nd test with short-acting tetracosactrin led to a rise in plasma cortisol in term and pre-term foals during the 2-h test period.
1 context sentence(design, population, supporting numbers)
Summary · context
The changes in plasma cortisol concentration in the immediate postnatal period were examined in 3 groups of newborn foals and the response of the adrenal cortex to exogenous ACTH1-24 (tetracosactrin) was tested in 2 of these groups.
In this study, Cosyntropin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cosyntropin.
Report a problemFND-0630039105

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:37 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.